IMP3 Antibody

1. our study found that IMP3 expression was higher in the ovarian clear cell carcinoma than the high grade serous and endometrioid subtypes PMID: 29866423
2. IMP3 expression in uterine leiomyosarcoma could be a marker of a poor prognosis. PMID: 29077232
3. IMP3 positive pT1 EAC revealed higher levels of lymph node metastases. PMID: 29974234
4. IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.IMP3 expression is associated with poor prognosis in patients with non-small cell lung cancer brain metastases. PMID: 29209838
5. Study found IMP3 frequently overexpressed in many human neoplasms and show significant associations with adverse tumor features in esophageal adenocarcinomas and cancers of the urinary bladder, lung, stomach, and pancreas. PMID: 29115542
6. In this study, IMP3 at the nodal site resulted to be associated with low progression-free survival in small-intestine neuroendocrine neoplasms, independently of the Ki-67 index. PMID: 28210937
7. IMP3 may contribute to the aggressive behavior of metaplastic breast carcinoma , and that this expression could potentially be a prognostic marker PMID: 29146055
8. These findings suggest that IMP3 expression has prognostic value as a biomarker for chemosensitivity and overall survival in triple negative breast cancer PMID: 28756977
9. This study establishes p65 as a novel target of IMP3 in increasing glioma cell migration and underscores the significance of IMP3-p65 feedback loop for therapeutic targeting in GBM. PMID: 28465487
10. IMP3 has a similar specificity, but a better sensitivity, intensity, and extent of reactivity in comparison with AMACR, and may be used as an alternative to AMACR, in support of the diagnosis of BE-dysplasia and EAC PMID: 26766126

Show More

Hide All

HGNC: 14497

OMIM: 612980

KEGG: hsa:55272

STRING: 9606.ENSP00000326981

UniGene: Hs.513043